Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 8/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.41 |
| ▸ | KDR | P35968 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18170645 | 0.99 | KDR (0.41) | CHRNA7KCNH2KDRMAPTHRH3 | |
| SCHEMBL18170610 | 0.95 | KDR (0.41) | KDRMAPTMAPK14SMN1; SMN2LMNA | |
| SCHEMBL18171033 | 0.94 | KDR (0.42) | KDRMAPTMAPK14SMN1; SMN2LMNA | |
| SCHEMBL18170660 | 0.94 | CHRNA7 (0.42) | CHRNA7KCNH2KDRMAPTHRH3 | |
| SCHEMBL18170875 | 0.93 | KDR (0.42) | CHRNA7KCNH2KDRMAPTHRH3 | |
| SCHEMBL18170577 | 0.89 | KDR (0.42) | KDRMAPTSMN1; SMN2LMNATHRB | |
| SCHEMBL18170761 | 0.88 | KDR (0.50) | CHRNA7KCNH2KDRMAPTSMN1; SMN2 | |
| SCHEMBL18170854 | 0.88 | KDR (0.43) | KDRMAPTSMN1; SMN2LMNATHRB | |
| SCHEMBL18170508 | 0.87 | KDR (0.51) | CHRNA7KCNH2KDRMAPT | |
| SCHEMBL18171026 | 0.87 | CHRNA7 (0.47) | CHRNA7KCNH2KDRMAPTNAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9856216-B2 | Compounds as TNIK, IKKε and TBK1 inhibitors and pharmaceutical composition comprising same | GREEN CROSS CORPORATION (KR) | 2018-01-02 | — | — | US | claimed |
| US-20160311772-A1 | COMPOUNDS AS TNIK, IKKEPSILON AND TBK1 INHIBITORS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GREEN CROSS CORPORATION (KR) | 2016-10-27 | — | — | US | claimed |
| US-9856216-B2 | Compounds as TNIK, IKKε and TBK1 inhibitors and pharmaceutical composition comprising same | GREEN CROSS CORPORATION (KR) | 2018-01-02 | — | — | US | disclosed |
| US-20160311772-A1 | COMPOUNDS AS TNIK, IKKEPSILON AND TBK1 INHIBITORS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GREEN CROSS CORPORATION (KR) | 2016-10-27 | — | — | US | disclosed |
| US-20160311772-A1 | COMPOUNDS AS TNIK, IKKEPSILON AND TBK1 INHIBITORS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GREEN CROSS CORPORATION (KR) | 2016-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160311772-A1 | COMPOUNDS AS TNIK, IKKEPSILON AND TBK1 INHIBITORS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | TNIK, TNK1, NFKBIA | CHRNA7 2197/4885KCNH2 2704/4885KDR 1662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.